Sportradar (SRAD) Q2 2026 Earnings Call Transcript

Sportradar reported Q2 revenue of €378m (+19% YoY) and adjusted EBITDA of €76m (+19% YoY), driven by 27% growth in Betting & Gaming Content and contributions from the IMG ARENA acquisition. Management updated FY26 guidance to €1.518bn–€1.533bn revenue (+19%–21% constant-currency) and €360m–€368m adjusted EBITDA (+24%–27% constant-currency) despite a delay in completing prediction market deals and softer U.S. sports-book growth. The company generated €103m free cash flow (+23%) and repurchased $140m of shares during the quarter under an enhanced $250m program, while also upsizing its revolving credit facility to €250m (maturity extended to 2031, no debt outstanding).

Analysis

SRAD looks like a higher-quality way to express growth in regulated wagering adjacencies than the consumer-facing sportsbooks: it gets paid on infrastructure, data, and engagement, so it can monetize new channels like prediction markets without taking the same balance-sheet or hold-rate risk. The market is likely to overfocus on the lowered near-term guide, but the more important signal is that the company is still converting cash aggressively and buying back stock while the incremental opportunity set is shifting from legacy sportsbook growth to a broader ecosystem of exchanges, brokers, and market makers.

The second-order winner is not just SRAD; it is any venue where low-latency data and premium rights become a tollbooth. That favors high-quality rights holders and data suppliers, while commoditized affiliate and acquisition spend may become more volatile if prediction-market customer acquisition proves cheaper than expected. The loser set is more nuanced: DKNG and FLUT are not necessarily direct cannibalization victims today, but they face a worse mix if prediction markets siphon engagement in states where OSB growth is already mature and tax pressure is rising.

Catalyst path: near term, the stock can still trade down if investors anchor on the guidance reset and legal/regulatory noise around prediction markets. Over 1-3 months, the key proof points are Q3 integration revenue, conversion of the pending prediction-market pipeline, and whether the company can show that new products are additive rather than merely re-timed. Over 6-18 months, the thesis breaks only if state/federal legal challenges meaningfully constrain prediction-market rollout or if the new products fail to monetize at economics superior to legacy sportsbook contracts.

Key Decisions for Investors

• Initiate a tactical long SRAD position on any 5-8% post-earnings weakness; hold 3-6 months for Q3 event-season and prediction-market deal conversion, with upside from multiple expansion if management proves the new TAM is real.
• Pair trade: long SRAD / short DKNG for 1-3 months to isolate data-and-infrastructure monetization versus consumer-facing regulatory and tax risk; thesis fails if prediction-market regulation tightens sharply or DKNG shows stronger-than-expected U.S. acceleration.
• If already long SRAD, overlay with a partial hedge via short-dated puts around September legal headlines or exchange-launch dates; this is a good stock to own, but not a good one to own naked into regulatory volatility.
• Watchlist trigger: if prediction-market revenue exits 2026 below the low-teens millions implied by management tone, reduce exposure; if it ramps faster than expected and 2027 guidance re-sets up, add on any pullback.